We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
冠状动脉介入术后发生肝素诱导的血小板减少症抗栓治疗的药学监护.
- Authors
管文婕; 陈慧慧; 汪涛; 张晨晨; 陈延杰; 朱捷
- Abstract
Objective To explore clinical pharmacists' role in antithrombotic therapy for acute myocardial infarction (AMI) inpatients with heparin-induced thrombocytopenia (HIT) after percutaneous coronary intervention (PCI). Methods Clinical pharmacists used the acute coronary syndrome clinical risk score (GRACE) and anti-platelet and anticoagulant treatment bleeding risk score (Crusade) to assess the risk of ischemia and bleeding in order to adjust the dose for antiplatelet therapy. The causes of thrombocytopenia and coagulation were evaluated. The possible medication related factors were identified for HIT patient. Argatroban was used to replace anticoagulant therapy and APTT was closely monitored in order to adjust dose in a timely manner. Warfarin was recommended for the discharged patients based on the mechanism of action, adverse reactions, safety and economics. Results No bleeding or thromboembolic complications was observed on the patient with argatroban for anticoagulant therapy and aspirin plus clopidogrel as maintenance therapy. Conclusion With good understanding in pharmacology and pharmacokinetics, clinical pharmacists can help doctors to solve the problems related to drug therapy in time. Therefore, better pharmaceutical care can be provided to patients with improved medication safety and rationality.
- Publication
Journal of Pharmaceutical Practice & Service, 2019, Vol 37, Issue 4, p370
- ISSN
1006-0111
- Publication type
Article
- DOI
10.3969/j.issn.1006-0111.2019.04.017